Document is current
Any future updates will be listed below
-
Authors
Tran, Florian
Scharmacher, Alena
Baran, Nathan
Mishra, Neha
Wozny, Marek
Chavez, Samuel Pineda
Bhardwaj, Archana
Hinz, Sophia
Juzenas, Simonas
Bernardes, Joana P.
Sievers, Laura Katharina
Lessing, Matthias
Aden, Konrad
Lassen, Arne
Bergfeld, Arne
Weber, Hauke Jann
Neas, Lennart
Vetrano, Stefania
Schreiber, Stefan
Rosenstiel, Philip
-
Funding
Funding for this research was provided by:
Innovative Medicines Initiative (853995)
Bundesministerium für Bildung und Forschung (01ZX1902A)
Deutsche Forschungsgemeinschaft (390884018)
Universitätsklinikum Schleswig-Holstein - Campus Kiel
- License Information
-
More Information
Article History
Received: 29 February 2024
Accepted: 7 May 2024
First Online: 13 May 2024
Competing interests
: The authors declare no competing interests related to the conception and results of this study. Financial disclosures: F.T. received speaker’s fees from Abbvie, Bristol-Myers-Squibb, Celltrion Healthcare, Dr Falk Pharma, Eli Lilly, Ferring Pharmaceuticals, Janssen, and funding from Sanofi/Regeneron. K.A. received speaker`s fees from Abbvie, Dr Falk Pharma, Eli Lilly, Janssen, Takeda and Galapagos. S.S. received consulting fees from AbbVie, Amgen, Arena, Boehringer Ingelheim, Bristol-Myers-Squibb, Celltrion Healthcare, Dr Falk Pharma, Eli Lilly, Ferring Pharmaceuticals, Galapagos/Gilead Sciences, Genentech/Roche, GlaxoSmithKline, IMAB Biopharma, MSD, Pfizer, Shire, and Takeda. All other authors have no conflicts of interest to declare.
